Study S001487

NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT01511198
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 223
Start: 2001-02
Primary completion: 2001-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:metformin
Results posted: FALSE

Registered primary outcomes

Body weight []

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023483	Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care	2015	Systematic review	PMID 25504028 DOI	registry reference RESULT:25504028
R0023484	Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Feinglos MN, Diabetic medicine : a journal of the British Diabetic Association	2005	Randomized trial	PMID 16026367 DOI	registry reference RESULT:16026367